Which blood product has the highest incidence of Transfusion-Related Acute Lung Injury (TRALI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Fresh Frozen Plasma Has the Highest Incidence of Transfusion-Related Acute Lung Injury (TRALI)

Fresh frozen plasma (FFP) has been identified as the blood component with the highest risk for causing TRALI due to its high plasma volume and potential for containing leukocyte antibodies. 1

Why FFP Has the Highest TRALI Risk

  • FFP and platelet concentrates are the most frequently implicated blood products in TRALI, with FFP having the highest risk 2, 1
  • The TRALI risk per component is 6.9 times higher for FFP than for red blood cells 3
  • FFP contains high concentrations of plasma, which may contain donor antibodies (particularly from female donors) that can react with recipient leukocytes 1, 4
  • These antibodies, particularly anti-HLA and anti-neutrophil antibodies, are the primary cause of immunogenic TRALI 4

Pathophysiology of TRALI

  • TRALI is primarily caused by donor antibodies that recognize leukocyte antigens in the transfused recipient (immunogenic TRALI) 4
  • These antibodies trigger neutrophil activation in the pulmonary vasculature, leading to endothelial damage and capillary leak 4
  • Non-immunogenic TRALI can also occur due to biologically active lipids that accumulate during storage of blood products 4
  • The "two-hit" model explains why critically ill patients are more susceptible to TRALI - they often have pre-existing inflammatory conditions that prime neutrophils (first hit), making them more reactive to antibodies or biological response modifiers in transfused products (second hit) 5

Evidence for FFP as Highest Risk Product

  • Studies have shown that the risk of TRALI due to FFP was 15.5 per million units issued compared to lower rates for other blood components 3
  • In donors of implicated FFP/platelets, white blood cell antibodies were found 3.6 times more often than by chance (p ≤ 0.0001) 3
  • Female donors were particularly implicated in TRALI cases, as they are more likely to have developed leukocyte antibodies during pregnancy 3, 6

Risk Reduction Strategies

  • Implementation of male-only plasma for component therapy has significantly reduced TRALI incidence 1, 6
  • After introducing male-only plasma policies, the risk of highly likely/probable TRALI due to FFP fell from 15.5 per million units to 3.2 per million units (p = 0.0079) 3
  • The Netherlands reported a 33% reduction in TRALI cases after implementing male-only plasma policies 6
  • Blood banks now routinely screen donors for leukocyte antibodies to further reduce risk 1, 7

Clinical Implications

  • TRALI presents with acute respiratory distress within 6 hours of transfusion, with hypoxemia and bilateral pulmonary infiltrates 7
  • It must be differentiated from Transfusion-Associated Circulatory Overload (TACO), which presents with similar respiratory symptoms but includes cardiovascular changes and evidence of fluid overload 7
  • Management includes immediate cessation of transfusion, oxygen support, and sometimes mechanical ventilation 7, 8
  • Unlike TACO, diuretics are ineffective and potentially harmful in TRALI 7, 4

In summary, FFP carries the highest risk of TRALI among blood products due to its high plasma content and potential for containing leukocyte antibodies. The implementation of male-only plasma policies has significantly reduced this risk, confirming the causal relationship between FFP and TRALI.

References

Guideline

Transfusion-Related Complications

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Transfusion-related acute lung injury (TRALI)].

Pneumologie (Stuttgart, Germany), 2014

Guideline

Management of Transfusion-Related Acute Lung Injury (TRALI)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Transfusion Related Acute Lung Injury (TRALI): A Single Institution Experience of 15 Years.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.